Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers

Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual SPE procedure is generally time‐consuming and cost‐ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet ver...

Full description

Saved in:
Bibliographic Details
Published inJournal of mass spectrometry. Vol. 46; no. 7; pp. 705 - 711
Main Authors Zhang, Yizhong, Zhang, Guodong, Clarke, Philip A., Huang, Jeffrey T. J., Takahashi, Eddie, Muirhead, David, Steenwyk, Rick C., Lin, Zhaosheng
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.07.2011
Wiley
Subjects
Online AccessGet full text
ISSN1076-5174
1096-9888
1096-9888
DOI10.1002/jms.1941

Cover

Abstract Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual SPE procedure is generally time‐consuming and cost‐ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high‐throughput online SPE‐LC–MS/MS method, allowing simultaneous and high‐throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2–40 ng/ml for tPGDM and 0.5–100 ng/ml for tPGEM. Intra‐ and inter‐assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non‐smoking healthy volunteers. These results demonstrated that the high‐throughput online SPE‐LC–MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. Copyright © 2011 John Wiley & Sons, Ltd.
AbstractList Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual SPE procedure is generally time‐consuming and cost‐ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high‐throughput online SPE‐LC–MS/MS method, allowing simultaneous and high‐throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2–40 ng/ml for tPGDM and 0.5–100 ng/ml for tPGEM. Intra‐ and inter‐assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non‐smoking healthy volunteers. These results demonstrated that the high‐throughput online SPE‐LC–MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. Copyright © 2011 John Wiley & Sons, Ltd.
Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD.
Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD.Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD.
Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 ?C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD.
Author Lin, Zhaosheng
Huang, Jeffrey T. J.
Zhang, Yizhong
Muirhead, David
Zhang, Guodong
Clarke, Philip A.
Steenwyk, Rick C.
Takahashi, Eddie
Author_xml – sequence: 1
  givenname: Yizhong
  surname: Zhang
  fullname: Zhang, Yizhong
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 2
  givenname: Guodong
  surname: Zhang
  fullname: Zhang, Guodong
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 3
  givenname: Philip A.
  surname: Clarke
  fullname: Clarke, Philip A.
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 4
  givenname: Jeffrey T. J.
  surname: Huang
  fullname: Huang, Jeffrey T. J.
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 5
  givenname: Eddie
  surname: Takahashi
  fullname: Takahashi, Eddie
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 6
  givenname: David
  surname: Muirhead
  fullname: Muirhead, David
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 7
  givenname: Rick C.
  surname: Steenwyk
  fullname: Steenwyk, Rick C.
  organization: Pfizer, Inc., Groton, CT 06340, USA
– sequence: 8
  givenname: Zhaosheng
  surname: Lin
  fullname: Lin, Zhaosheng
  email: joe-zhaosheng.lin@pfizer.com
  organization: Pfizer, Inc., Groton, CT 06340, USA
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24332242$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21706677$$D View this record in MEDLINE/PubMed
BookMark eNp9kV2P1CAYhYlZ435o4i8w3Bi96SxQCuXSjLPjx1Q3qcZLQlu6w9rCLNDo_AV_tYwz7qpRryDkOYf3PecUHFlnNQCPMZphhMj59RhmWFB8D5xgJFgmyrI82t05ywrM6TE4DeEaISQEZQ_AMcEcMcb5CfhWm3EaorLaTQEq28G1uVpnce3ddLXeTBHeTMpGE1U0zkLXw8kbq_wWRh29ss7Dy-XL6ofyl5dFBZstdHYwVsP6cpGt5llVn1c1VAEa2w9qHFV0yaYxblT-s_bhIbjfqyHoR4fzDHy8WHyYv8pW75ev5y9WWUtLjrOmIHnamXOMS8YUwph3ZU4oUlj0RS66llFCu6Irte4KIXKKG9I0vClaTjDN8zPwbO-78e5m0iHK0YRWD8M-BFlyigXOqUjk8_-SGBFSMo6LMqFPDujUjLqTG2_SWlv5M-kEPD0AKrRq6FNSrQl3XBqMEEru_my9C8Hr_hbBSO7KlqlsuSs7obM_0PbQU-rBDH8TZHvBFzPo7T-N5Zuq_p03Ieqvt3yqSzKe80J-ereUhM_fFhcieeTfAa7sx1A
CitedBy_id crossref_primary_10_1002_bmc_4102
crossref_primary_10_1161_JAHA_123_032835
crossref_primary_10_1111_all_14741
crossref_primary_10_1016_j_jpba_2015_02_011
crossref_primary_10_1166_jbn_2024_3807
crossref_primary_10_1016_j_freeradbiomed_2019_03_017
crossref_primary_10_1080_10408347_2022_2035210
crossref_primary_10_1194_jlr_D023739
crossref_primary_10_1096_fj_201802547R
crossref_primary_10_3390_molecules23123275
crossref_primary_10_1002_jssc_201200056
crossref_primary_10_1002_rcm_6963
crossref_primary_10_1016_j_bbrc_2016_12_151
crossref_primary_10_1016_j_cca_2013_03_031
crossref_primary_10_1016_j_jchromb_2014_01_046
crossref_primary_10_1016_j_prostaglandins_2019_106361
crossref_primary_10_1155_2021_5591115
crossref_primary_10_1016_j_jpba_2016_06_017
crossref_primary_10_1016_j_plefa_2014_09_006
crossref_primary_10_4155_bio_2018_0173
crossref_primary_10_1111_all_12376
crossref_primary_10_3390_nu14071319
crossref_primary_10_1166_jbt_2022_3113
crossref_primary_10_3390_metabo11020106
crossref_primary_10_1183_13993003_01390_2016
crossref_primary_10_1038_s41598_017_17798_w
Cites_doi 10.1172/JCI27540
10.1016/0262-1746(87)90010-2
10.1016/j.cgh.2006.07.015
10.1016/j.molimm.2008.04.014
10.1016/S0083-6729(00)58022-4
10.1002/jps.2600620406
10.1158/1078-0432.CCR-05-0733
10.1016/0090-6980(89)90088-9
10.1016/0090-6980(76)90160-X
10.1016/j.ab.2004.08.019
10.1016/j.freeradbiomed.2009.10.047
10.1016/j.jchromb.2008.06.042
10.4049/jimmunol.179.5.2766
10.1016/j.jaci.2004.04.041
10.1074/jbc.M706839200
10.1016/S0022-3565(25)10713-1
ContentType Journal Article
Copyright Copyright © 2011 John Wiley & Sons, Ltd.
2015 INIST-CNRS
Copyright_xml – notice: Copyright © 2011 John Wiley & Sons, Ltd.
– notice: 2015 INIST-CNRS
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7SR
7U5
8BQ
8FD
JG9
L7M
7X8
DOI 10.1002/jms.1941
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Engineered Materials Abstracts
Solid State and Superconductivity Abstracts
METADEX
Technology Research Database
Materials Research Database
Advanced Technologies Database with Aerospace
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Materials Research Database
Engineered Materials Abstracts
Solid State and Superconductivity Abstracts
Technology Research Database
Advanced Technologies Database with Aerospace
METADEX
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef
MEDLINE - Academic
Materials Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1096-9888
EndPage 711
ExternalDocumentID 21706677
24332242
10_1002_jms_1941
JMS1941
ark_67375_WNG_27CK5F90_1
Genre article
Journal Article
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHBH
AAHQN
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIJN
ACAHQ
ACBWZ
ACCZN
ACGFS
ACIWK
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFNX
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AI.
AIDQK
AIDYY
AITYG
AIURR
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AQPKS
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BNHUX
BROTX
BRXPI
BSCLL
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RNS
ROL
RX1
RYL
SAMSI
SUPJJ
TN5
TUS
UB1
UQL
V2E
VH1
W8V
W99
WBFHL
WBKPD
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRJ
WXSBR
WYISQ
XG1
XPP
XV2
ZCG
ZZTAW
~02
~IA
~KM
~WT
AAHHS
ACCFJ
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
RWI
WRC
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7SR
7U5
8BQ
8FD
JG9
L7M
7X8
ID FETCH-LOGICAL-c4871-b5230027711866a0117d83240a19f539dc6424d5d8eed599341b2bb7b5c721433
IEDL.DBID DR2
ISSN 1076-5174
1096-9888
IngestDate Thu Sep 04 21:40:39 EDT 2025
Fri Sep 05 13:44:34 EDT 2025
Thu Apr 03 07:07:49 EDT 2025
Mon Jul 21 09:14:50 EDT 2025
Sun Sep 21 06:14:28 EDT 2025
Thu Apr 24 22:55:17 EDT 2025
Wed Jan 22 16:29:49 EST 2025
Tue Sep 09 05:29:33 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Solid phase extraction
Biological fluid
Tandem mass spectrometry
Chemical analysis
Metabolite
HPLC chromatography
Biological marker
Prostaglandin E2
Electrospray
Chemical enrichment
Sample preparation
LC―MS/MS
Bronchus disease
Chronic obstructive pulmonary disease
Obstructive pulmonary disease
tetranor PGEM
Quantitative analysis
Trace analysis
Human
Urine
Validation
Healthy subject
Coupled method
Respiratory disease
Elimination
Patient
Prostaglandin D2
PGD
biomarker
PGE
Mass spectrometry
COPD
tetranor PGDM
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
Copyright © 2011 John Wiley & Sons, Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4871-b5230027711866a0117d83240a19f539dc6424d5d8eed599341b2bb7b5c721433
Notes istex:6C142311C7F2E975E7EF223F12E670EB6CFEA2AA
ArticleID:JMS1941
ark:/67375/WNG-27CK5F90-1
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 21706677
PQID 1022867158
PQPubID 23500
PageCount 7
ParticipantIDs proquest_miscellaneous_874191349
proquest_miscellaneous_1022867158
pubmed_primary_21706677
pascalfrancis_primary_24332242
crossref_primary_10_1002_jms_1941
crossref_citationtrail_10_1002_jms_1941
wiley_primary_10_1002_jms_1941_JMS1941
istex_primary_ark_67375_WNG_27CK5F90_1
PublicationCentury 2000
PublicationDate July 2011
PublicationDateYYYYMMDD 2011-07-01
PublicationDate_xml – month: 07
  year: 2011
  text: July 2011
PublicationDecade 2010
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: Chichester
– name: England
PublicationTitle Journal of mass spectrometry.
PublicationTitleAlternate J. Mass Spectrom
PublicationYear 2011
Publisher John Wiley & Sons, Ltd
Wiley
Publisher_xml – name: John Wiley & Sons, Ltd
– name: Wiley
References Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, G. A. Fitzgerald, Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 2006, 116, 1391.
L. J. Murphey, M. K. Williams, S. C. Sanchez, L. M. Byrne, I. Csiki, J. A. Oates, D. H. Johnson, J. D. Morrow, Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334, 266.
S. M. Jachak, PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr. Opin. Invest. Drugs 2007, 8, 411.
D. C. Monkhouse, L. Van Campen, A. J. Aguiar, Kinetics of dehydration and isomerization of prostaglandins E1 and E2. J. Pharm. Sci. 1973, 62, 576.
R. Vassallo, P. R. Kroening, J. Parambil, H. Kita, Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol. Immunol. 2008, 45, 3321.
W. L. Song, M. Wang, E. Ricciotti, S. Fries, Y. Yu, T. Grosser, M. Reilly, J. A. Lawson, G. A. FitzGerald, Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283, 1179.
Y. Urade, O. Hayaishi, Prostaglandin D synthase: structure and function. Vitam. Horm. 2000, 58, 89.
C. C. Lin, I. T. Lee, Y. L. Yang, C. W. Lee, Y. R. Kou, C. M. Yang, Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: role of TLR4-dependent NADPH oxidase activation. Free Radic. Biol. Med. 2010, 48, 240.
R. H. Pullen, J. A. Howell, J. W. Cox, High performance liquid chromatographic determination of thromboxane B2 in human serum as a methoxime-panacylester derivative. Prostaglandins Leukot. Med. 1987, 29, 205.
J. R. Neale, B. J. Dean, Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871, 72.
H. W. Seyberth, B. J. Sweetman, J. C. Frolich, J. A. Oates, Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976, 11, 381.
Y. Chen, B. Perussia, K. S. Campbell, Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J. Immunol. 2007, 179, 2766.
C. C. Chan, S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. G. Hill, C. S. Li, J. Mancini, M. Penneton, et al, Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 1995, 274, 1531.
N. D. Gross, J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, A. J. Duffield-Lillico, Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin. Cancer Res. 2005, 11, 6087.
J. C. Johnson, C. R. Schmidt, M. J. Shrubsole, D. D. Billheimer, P. R. Joshi, J. D. Morrow, M. J. Heslin, M. K. Washington, R. M. Ness, W. Zheng, D. A. Schwartz, R. J. Coffey, R. D. Beauchamp, N. B. Merchant, Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2006, 4, 1358.
J. D. Morrow, W. G. Parsons III, L. J. Roberts II, Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38, 263.
P. H. Howarth, A. J. Knox, Y. Amrani, O. Tliba, R. A. Panettieri Jr., M. Johnson, Synthetic responses in airway smooth muscle. J. Allergy Clin. Immunol. 2004, 114, S32.
2007; 179
1973; 62
2010; 48
2004; 114
2004; 334
1976; 11
2000; 58
2007; 8
2008; 45
2006; 4
2006; 116
2008; 871
1995; 274
1989; 38
2005; 11
2008; 283
1987; 29
Jachak S. M. (e_1_2_6_3_2) 2007; 8
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_18_2
Chan C. C. (e_1_2_6_6_2) 1995; 274
e_1_2_6_9_2
e_1_2_6_4_2
e_1_2_6_5_2
e_1_2_6_12_2
e_1_2_6_13_2
e_1_2_6_2_2
e_1_2_6_10_2
e_1_2_6_11_2
e_1_2_6_16_2
e_1_2_6_17_2
e_1_2_6_14_2
e_1_2_6_15_2
References_xml – reference: J. C. Johnson, C. R. Schmidt, M. J. Shrubsole, D. D. Billheimer, P. R. Joshi, J. D. Morrow, M. J. Heslin, M. K. Washington, R. M. Ness, W. Zheng, D. A. Schwartz, R. J. Coffey, R. D. Beauchamp, N. B. Merchant, Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2006, 4, 1358.
– reference: D. C. Monkhouse, L. Van Campen, A. J. Aguiar, Kinetics of dehydration and isomerization of prostaglandins E1 and E2. J. Pharm. Sci. 1973, 62, 576.
– reference: R. H. Pullen, J. A. Howell, J. W. Cox, High performance liquid chromatographic determination of thromboxane B2 in human serum as a methoxime-panacylester derivative. Prostaglandins Leukot. Med. 1987, 29, 205.
– reference: R. Vassallo, P. R. Kroening, J. Parambil, H. Kita, Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol. Immunol. 2008, 45, 3321.
– reference: S. M. Jachak, PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr. Opin. Invest. Drugs 2007, 8, 411.
– reference: N. D. Gross, J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, A. J. Duffield-Lillico, Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin. Cancer Res. 2005, 11, 6087.
– reference: Y. Urade, O. Hayaishi, Prostaglandin D synthase: structure and function. Vitam. Horm. 2000, 58, 89.
– reference: C. C. Chan, S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. G. Hill, C. S. Li, J. Mancini, M. Penneton, et al, Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 1995, 274, 1531.
– reference: L. J. Murphey, M. K. Williams, S. C. Sanchez, L. M. Byrne, I. Csiki, J. A. Oates, D. H. Johnson, J. D. Morrow, Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334, 266.
– reference: C. C. Lin, I. T. Lee, Y. L. Yang, C. W. Lee, Y. R. Kou, C. M. Yang, Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: role of TLR4-dependent NADPH oxidase activation. Free Radic. Biol. Med. 2010, 48, 240.
– reference: P. H. Howarth, A. J. Knox, Y. Amrani, O. Tliba, R. A. Panettieri Jr., M. Johnson, Synthetic responses in airway smooth muscle. J. Allergy Clin. Immunol. 2004, 114, S32.
– reference: Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, G. A. Fitzgerald, Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 2006, 116, 1391.
– reference: J. R. Neale, B. J. Dean, Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871, 72.
– reference: J. D. Morrow, W. G. Parsons III, L. J. Roberts II, Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38, 263.
– reference: W. L. Song, M. Wang, E. Ricciotti, S. Fries, Y. Yu, T. Grosser, M. Reilly, J. A. Lawson, G. A. FitzGerald, Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283, 1179.
– reference: Y. Chen, B. Perussia, K. S. Campbell, Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J. Immunol. 2007, 179, 2766.
– reference: H. W. Seyberth, B. J. Sweetman, J. C. Frolich, J. A. Oates, Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976, 11, 381.
– volume: 274
  start-page: 1531
  year: 1995
  article-title: Pharmacology of a selective cyclooxygenase‐2 inhibitor, L‐745,337: a novel nonsteroidal anti‐inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 48
  start-page: 240
  year: 2010
  article-title: Induction of COX‐2/PGE(2)/IL‐6 is crucial for cigarette smoke extract‐induced airway inflammation: role of TLR4‐dependent NADPH oxidase activation
  publication-title: Free Radic. Biol. Med.
– volume: 116
  start-page: 1391
  year: 2006
  article-title: Cyclooxygenases, microsomal prostaglandin E synthase‐1, and cardiovascular function
  publication-title: J. Clin. Invest.
– volume: 8
  start-page: 411
  year: 2007
  article-title: PGE synthase inhibitors as an alternative to COX‐2 inhibitors
  publication-title: Curr. Opin. Invest. Drugs
– volume: 45
  start-page: 3321
  year: 2008
  article-title: Nicotine and oxidative cigarette smoke constituents induce immune‐modulatory and pro‐inflammatory dendritic cell responses
  publication-title: Mol. Immunol.
– volume: 334
  start-page: 266
  year: 2004
  article-title: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase‐specific PGE2 synthesis in healthy humans and those with lung cancer
  publication-title: Anal. Biochem.
– volume: 11
  start-page: 381
  year: 1976
  article-title: Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies
  publication-title: Prostaglandins
– volume: 11
  start-page: 6087
  year: 2005
  article-title: Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers
  publication-title: Clin. Cancer Res.
– volume: 179
  start-page: 2766
  year: 2007
  article-title: Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor
  publication-title: J. Immunol.
– volume: 29
  start-page: 205
  year: 1987
  article-title: High performance liquid chromatographic determination of thromboxane B2 in human serum as a methoxime‐panacylester derivative
  publication-title: Prostaglandins Leukot. Med.
– volume: 58
  start-page: 89
  year: 2000
  article-title: Prostaglandin D synthase: structure and function
  publication-title: Vitam. Horm.
– volume: 62
  start-page: 576
  year: 1973
  article-title: Kinetics of dehydration and isomerization of prostaglandins E1 and E2
  publication-title: J. Pharm. Sci.
– volume: 38
  start-page: 263
  year: 1989
  article-title: Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid
  publication-title: Prostaglandins
– volume: 283
  start-page: 1179
  year: 2008
  article-title: Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans
  publication-title: J. Biol. Chem.
– volume: 871
  start-page: 72
  year: 2008
  article-title: Liquid chromatography‐tandem mass spectrometric quantification of the dehydration product of tetranor PGE‐M, the major urinary metabolite of prostaglandin E(2) in human urine
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– volume: 114
  start-page: S32
  year: 2004
  article-title: Synthetic responses in airway smooth muscle
  publication-title: J. Allergy Clin. Immunol.
– volume: 4
  start-page: 1358
  year: 2006
  article-title: Urine PGE‐M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia
  publication-title: Clin. Gastroenterol. Hepatol.
– ident: e_1_2_6_11_2
  doi: 10.1172/JCI27540
– ident: e_1_2_6_15_2
  doi: 10.1016/0262-1746(87)90010-2
– ident: e_1_2_6_13_2
  doi: 10.1016/j.cgh.2006.07.015
– volume: 8
  start-page: 411
  year: 2007
  ident: e_1_2_6_3_2
  article-title: PGE synthase inhibitors as an alternative to COX‐2 inhibitors
  publication-title: Curr. Opin. Invest. Drugs
– ident: e_1_2_6_7_2
  doi: 10.1016/j.molimm.2008.04.014
– ident: e_1_2_6_2_2
  doi: 10.1016/S0083-6729(00)58022-4
– ident: e_1_2_6_10_2
  doi: 10.1002/jps.2600620406
– ident: e_1_2_6_8_2
  doi: 10.1158/1078-0432.CCR-05-0733
– ident: e_1_2_6_18_2
  doi: 10.1016/0090-6980(89)90088-9
– ident: e_1_2_6_17_2
  doi: 10.1016/0090-6980(76)90160-X
– ident: e_1_2_6_12_2
  doi: 10.1016/j.ab.2004.08.019
– ident: e_1_2_6_4_2
  doi: 10.1016/j.freeradbiomed.2009.10.047
– ident: e_1_2_6_14_2
  doi: 10.1016/j.jchromb.2008.06.042
– ident: e_1_2_6_16_2
  doi: 10.4049/jimmunol.179.5.2766
– ident: e_1_2_6_5_2
  doi: 10.1016/j.jaci.2004.04.041
– ident: e_1_2_6_9_2
  doi: 10.1074/jbc.M706839200
– volume: 274
  start-page: 1531
  year: 1995
  ident: e_1_2_6_6_2
  article-title: Pharmacology of a selective cyclooxygenase‐2 inhibitor, L‐745,337: a novel nonsteroidal anti‐inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1016/S0022-3565(25)10713-1
SSID ssj0009946
Score 2.1218693
Snippet Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual...
Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 705
SubjectTerms Acceptability
Assaying
Biological and medical sciences
biomarker
Biomarkers - urine
Chronic obstructive pulmonary disease, asthma
COPD
High-Throughput Screening Assays - methods
Human
Humans
Inflammation - urine
Investigative techniques, diagnostic techniques (general aspects)
LC-MS/MS
Least-Squares Analysis
Mass spectrometry
Medical sciences
On-line systems
Online
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Patients
PGD2
PGE2
Pneumology
Prostaglandin D2 - analogs & derivatives
Prostaglandin D2 - urine
Prostaglandins - urine
Pulmonary Disease, Chronic Obstructive - urine
Reproducibility of Results
Respiratory system
Sensitivity and Specificity
Smoking
Solid Phase Extraction - methods
Tandem Mass Spectrometry - methods
tetranor PGDM
tetranor PGEM
Urine
validation
Title Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers
URI https://api.istex.fr/ark:/67375/WNG-27CK5F90-1/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjms.1941
https://www.ncbi.nlm.nih.gov/pubmed/21706677
https://www.proquest.com/docview/1022867158
https://www.proquest.com/docview/874191349
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1076-5174
  databaseCode: DR2
  dateStart: 19960101
  customDbUrl:
  isFulltext: true
  eissn: 1096-9888
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009946
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQOcCF9yM8KiMhOGV3k9ib-IiW3VaFVBWhohIHy4-sxKPZskkk4NSfUIl_2F_CjJ3ssqiVEKdI0djx2ON4xv78DSHPjbUjkyYijBM2Dllc2lBpY0JlYP2zRljt2Pbz_fHuIds74kcdqhLvwnh-iNWGG84M97_GCa50PVyThn4-rgcQgWPkEyXcndC-WzNHCeEvFkGYHiIZc887O4qHfcGNlegqdup3REaqGjpn7rNaXOR2bnqxbhma3SQfewU8-uTLoG30wPz8i9vx_zS8RW503il95c3pNrlSVnfItUmfFO4uOSs-IQRRVeWiramqLEW-4_PTsy7fz0nb0G-tqpqO-psu5hT386ERtCkb0HexpAc7r3NX9o8305zqH9S3mhYHU6jy7eT89FdeDPOCqprCTADjPXagAIqkAYgrWtb3yOFs-n6yG3ZJHUIDsVEUatyGxoPjCKn2FFLS2QxZAVUk5jwR1kBExCy3GazeHLwnFulY61RzA8EqS5L7ZKtaVOVDRGVB7MhMBFWljEcQa4_nXI-YFiop04wF5GU_wNJ0amPija_SczXHEnpYYg8H5NlK8sSzfFwg88LZyEoA1ERUXMrlh_0dGaeTN3wmoFBAtjeMaFUgRq44cInga71VSRg-PKHxwyYx_EbCQZ4FhF4ik4EPiHAJEZAH3iLXH0AupHGaQlOdXV2qi9zLC3w--lfBx-S630xHnPITstUs2_IpeGON3nbz7jebjjLK
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBaK9tBd9n54j04Dhu3kJH4otrDTkCbN2jgo5hbrYYCghwPsUaeLbWDbqT-hwP5hf8lIy06WoQWGnQwYlCxKpEVS1EdCXmpjejoKuOsHYd8N_cy4UmntSg37n9HcqBptP5n2x8fh_gk72SBv2rswFh9iGXBDzaj_16jgGJDurlBDP58WHXDBwfXZwuM51Mrd9yvsKM7t1SJw1F2EY26RZ3t-t225thdt4bR-x9xIWcD0zGxdi6sMz3U7tt6IRrfIx5YFm3_ypVOVqqN__oXu-J883iY3GwOVvrUSdYdsZPldsj1o68LdIxfpJ8xClHk2rwoqc0MR8vjy_KIp-XNWlfRbJfOyQf-m8xnFkD6MgpZZCQzPF_Rwbzep2_7xZphQ9YPaYdP0cAhdTgaX57-StJukVBYUlAHk97TOC6CIG4CpRYviPjkeDY8GY7ep6-BqcI88V2EkGs-OPUTbk4hKZ2IEBpQen7GAGw1OUWiYiWEDZ2BAhZ7ylYoU0-CvhkHwgGzm8zx7hIlZ4D6G2oOuIhABcLf7M6Z6oeIyyKI4dMjrdoWFbtjG2htfhYVr9gXMsMAZdsiLJeWZBfq4guZVLSRLAmATE-MiJj5M94QfDQ7YiEMjh-ysSdGygY9wcWAVwddasRKwfHhIY5dNoAeOmIMsdgi9hiYGMxAzJrhDHlqRXH0A4ZD6UQRDrQXrWl7EfpLi8_G_Ej4n2-OjZCIm76YHT8gNG1vHtOWnZLNcVNkzMM5KtVMr4W-gWzbm
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2hVgJeuFPMpSwSgicnsb3ryyNKk5a2jiJMRSUerL3YErR1QmxLwFM_oRJ_2C9hxmsnBLUS4imSNWvv7M5m56yPzxDyWmk9UIEX2a7HfJu5mbaFVMoWCvY_rSItG7X9eOLvHbH9Y37csirxWxijD7E8cMOV0fxf4wKf67y_Eg39elb2AIED8tlkPoArTIg-rKSjosh8WQQ43UY15k54duD2u5ZrW9Emjup3pEaKEkYnN2Utrso719PYZh8a3yWfOw8M_eSkV1eyp37-Je74fy7eI3fa9JS-M_F0n9zIigfk1rCrCveQXCRfkIMoimxWl1QUmqLg8eX5RVvwZ15X9FstiqrV_qaznOKBPnSCVlkF_s4WdLq7Ezdt_7gyiqn8QU2vaTIdwS0Ph5fnv-KkHydUlBSWAkTvWcMKoKgagMSiRfmIHI1HH4d7dlvVwVYAjhxb4jk0vjl2UGtPoCadDlEWUDhRzr1IK4BETHMdwvbNIX1ijnSlDCRXgFaZ5z0mG8WsyJ4gLQvAI1MO3Cpg3AGw7edcDpiMhJcFIbPI226CU9W6jZU3TlMj1uymMMIpjrBFXi0t50bm4wqbN02MLA3ATaTFBTz9NNlN3WB4wMcRNLLI9loQLRu4KBYHORE8rYuqFKYPX9GYaUsRf6PiIA8tQq-xCSEJRL5EZJEtE5GrB6AYkh8E0NUmrq71Jd2PE_x9-q-GL8nN6c44PXw_OXhGbpuDdeQsPycb1aLOXkBmVsntZgn-BtrQNZU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simultaneous+and+high-throughput+quantitation+of+urinary+tetranor+PGDM+and+tetranor+PGEM+by+online+SPE-LC-MS%2FMS+as+inflammatory+biomarkers&rft.jtitle=Journal+of+mass+spectrometry.&rft.au=Zhang%2C+Yizhong&rft.au=Zhang%2C+Guodong&rft.au=Clarke%2C+Philip+A&rft.au=Huang%2C+Jeffrey+T+J&rft.date=2011-07-01&rft.issn=1096-9888&rft.eissn=1096-9888&rft.volume=46&rft.issue=7&rft.spage=705&rft_id=info:doi/10.1002%2Fjms.1941&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-5174&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-5174&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-5174&client=summon